Cardiologists treating patients with atherosclerotic cardiovascular disease are increasingly initiating semaglutide as a cardiovascular risk modifier, adding an estimated 4.8 million new commercial GLP-1 patients annually
For Wegovy (once-weekly semaglutide) , recommendations depend on several factors including: Your individual risk profile Whether you're in the dose escalation phase The presence of significant gastrointestinal symptoms Local endoscopy unit policies Many patients can safely continue Wegovy before colonoscopy under moderate sedation
Store the injection according to the manufacturers storage instructions, including refrigeration requirements
She also received the George L
Most patients taking both medications without other serotonergic agents experience no problems when monitored appropriately
Drugs that treat other Alzheimers risk factors, like herpes virus infection or high cholesterol, dont seem to benefit people with the disease in well-controlled clinical trials